Seeking Alpha

Cell Therapeutics (CTIC) +32.4% premarket after receiving a positive opinion for...

Cell Therapeutics (CTIC+32.4% premarket after receiving a positive opinion for conditional approval of its pixuvri lymphoma treatment from the European Medicines Agency. CTIC expects that a marketing authorization should be granted by the European Commission within a few months.
Comments (1)
  • cholee65
    , contributor
    Comments (38) | Send Message
     
    CTIC has been the biggest biotech loser over the past 10 years. If you want a good long take a look at ASTX it's profile is very similar to SPPI which went from $2-$15. Also, take a look at OVIT; CEO's last company Genzyme bought for $26 per share, this one trades at 26 cents.
    19 Feb 2012, 12:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|